Astria Reports Positive Interim Data for Navenibart in HAE Trial

Astria Therapeutics has shared promising initial results from its ongoing ALPHA-SOLAR trial evaluating navenibart (STAR-0215), a plasma kallikrein inhibitor, in adults with hereditary angioedema (HAE) Type 1 or 2.

The open-label study demonstrated strong efficacy and safety, with the Q3M (every 3 months) dosing arm showing a 95% reduction in monthly attack rates and the Q6M (every 6 months) arm showing an 86% decrease. Notably, 50% of patients remained attack-free over six months.

All 16 participants from the earlier ALPHA-STAR trial enrolled in ALPHA-SOLAR. The antibody was well tolerated, with no serious treatment-emergent adverse events or discontinuations reported during over 17 months of cumulative follow-up.

These findings support the potential of navenibart as a long-acting, low-burden preventive therapy for HAE.

23-06-2025